Teicoplanin A2-4 |
| Catalog No.GC14637 |
glycopeptide antibiotic
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 91032-37-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Teicoplanin A2-4 is a major component of the teicoplanin complex [1-3].
Teicoplanins, lipoglycopeptide antibiotics, are glycopeptide antibiotics mainly produced by A. teichomyceticus that are broadly effective against Gram-positive bacteria in vitro. Teicoplanins consist of five major components (A2-1, A2-2, A2-3, A2-4 and A2-5), one hydrolysis component (A3-1), and four minor components (RS-1, RS-2, RS-3, RS-4) [1]. Teicoplanins have been recently used for the treatment of multitudinous aerobic and anaerobic Gram-positive infections. Teicoplanins have been rapidly and extensively absorbed from the peritoneal cavity and muscle, but very poorly absorbed from the gastrointestinal tract [2]. Teicoplanin is highly bound in plasma to albumin and in tissues. Both renal and nonrenal mechanisms have been implicated in the elimination of the drug. For at least after one day administration, the concentrations of teicoplanin in serum and urine exceeded the MIC ranging from 0.02-2 μg/ml on many pathogenic organisms [3].
References:
[1] Bernareggi A, Borghi A, Borgonovi M, et al. Teicoplanin metabolism in humans[J]. Antimicrobial agents and chemotherapy, 1992, 36(8): 1744-1749.
[2] Rowland M. Clinical pharmacokinetics of teicoplanin[J]. Clinical pharmacokinetics, 1990, 18(3): 184-209.
[3] Traina G L, Bonati M. Pharmacokinetics of teicoplanin in man after intravenous administration[J]. Journal of Pharmacokinetics and Pharmacodynamics, 1984, 12(2): 119-128.
| Cas No. | 91032-37-0 | SDF | |
| Chemical Name | 34-O-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-22,31-dichloro-7-demethyl-64-O-demethyl-19-deoxy-56-O-[2-deoxy-2-[(8-methyl-1-oxodecyl)amino]-β-D-glucopyranosyl]-42-O-α-D-mannopyranosyl-ristomycin A aglycone | ||
| Canonical SMILES | CCC(CCCCCC/C(O)=N/[C@]([C@@](OC1=C2C=C([C@](/N=C(O)\[C@](/N=C(O)/[C@@](/N=C(O)\[C@@](N)([H])C3=CC4=C(O)C=C3)([H])CC5=CC(Cl)=C(O2)C=C5)([H])C6=CC(O)=CC(O4)=C6)([H])/C(O)=N/[C@](/C(O)=N/7)([H])C8=CC(C9=C([C@@]%10([H])C(O)=O)C=C(O)C=C9O[C@]%11([H])[C@](O)([H | ||
| Formula | C89H99Cl2N9O33 | M.Wt | 1893.7 |
| Solubility | Soluble in ethanol;Soluble in methanol;Soluble in DMSO;Soluble in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5281 mL | 2.6403 mL | 5.2807 mL |
| 5 mM | 0.1056 mL | 0.5281 mL | 1.0561 mL |
| 10 mM | 0.0528 mL | 0.264 mL | 0.5281 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *